EC
DNTH icon

EntryPoint Capital’s Dianthus Therapeutics DNTH Stock Holding History

EntryPoint Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Buy
+4,232
New +$370K 0.1% 400
2024
Q2 		– Sell
-363
Closed -$10.9K – 1507
2024
Q1 		$10.9K Buy
+363
New +$7.89K 0.01% 1222

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

EntryPoint Capital's DNTH Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 4,232 shares worth $413K. The stake represents 0.1% of the portfolio and ranks #400 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in DNTH as recently as Q1 2024.

EntryPoint Capital first reported a position in DNTH in Q1 2024 and has held it in 2 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • EntryPoint Capital held 4,232 shares of Dianthus Therapeutics worth $413K as of Q2 2026.
  • Dianthus Therapeutics was a new EntryPoint Capital position in Q2 2026.
  • Dianthus Therapeutics made up 0.1% of EntryPoint Capital's portfolio in Q2 2026, its #400 holding.
  • EntryPoint Capital first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.